<DOC>
	<DOCNO>NCT02471963</DOCNO>
	<brief_summary>Empagliflozin may lead improved vascular endothelial function macro- ( pulse wave reflection ) microcirculation ( retinal circulation ) improve cardiovascular risk factor , imparticular effectively control hyperglycemia , arterial hypertension obesity .</brief_summary>
	<brief_title>Effect Empagliflozin Macrovascular Microvascular Circulation Endothelium Function</brief_title>
	<detailed_description>Diabetes mellitus , consider metabolic disorder , mutate predominantly vascular disease , duration extend several year and/or additional cardiovascular risk factor coexists , particular arterial hypertension . In accordance , patient type 2 diabetes die microvascular macrovascular complication , rarely hypoglycaemic hyperglycaemic shock syndrome . As consequence , treatment type 2 diabetes focus metabolic control also improve global vascular risk . Analyses compare importance various cardiovascular risk factor conclude reduction blood pressure lipid level significantly important reduction hyperglycemia . Of course , multidisciplinary approach desirable STENO-2 study clearly indicate mid-term microvascular complication long-term macrovascular complication prevent type 2 diabetes . Vascular change occur course type 2 diabetes , arterial hypertension elevate global cardiovascular risk reliably assess non-invasively , already early stage vascular remodeling process . For example , guideline European Society Hypertension recommend several vascular parameter assess already diagnosis disease order analyze early organ damage artery . The measurement pulse wave velocity , pulse wave analysis , central ( aortic ) systolic pressure pulse pressure tool detect early vascular change large artery relate faster wave reflection arterial tree . Wall lumen ratio retinal artery , retinal capillary flow flow mediate vasodilation tool detect change microvascular circulation . These parameter infrequently measure study type 2 diabetes , mainly due lack awareness vascular change key prognostic factor type-2 diabetes ultimately determine fate patient . Empagliflozin novel selective SLGT-2 inhibitor show improve glycaemic control 2 , 12 , 24 week well 1 2 year . Empagliflozin produce dose dependent increase glucosuria clinically meaningful change glycemic parameter type 2 diabetes addition weight loss . Most striking , empagliflozin also find low systolic blood pressure 5 mmHg . This reduction blood pressure might relate weight loss or/and concomitant loss total body sodium content . However , precise mechanism blood pressure reduction need elucidate . Loss sodium would lead less reactive contraction small artery response increase sympathetic activity , angiotensin II catecholamine . Moreover , endothelium dependent vasodilation reactive hyperemia new non-invasive tool detect change organ perfusion level . To assess flow-mediated/Endothelium dependent vasodilation ass EndoPAT Risk Score . These parameter infrequently measure study type 2 diabetes , mainly due lack expertise require assess vascular parameter lack awareness vascular change key prognostic factor type 2 diabetes ( glycosylated hemoglobin ) . In summary , empagliflozin exert beneficial effect variety cardiovascular risk factor , hyperglycaemia , hypertension obesity . These change lead ( hypothesis ) improve vascular endothelial function micro- macrocirculation . However , latter nothing hypothesis require clear proof clinical study patient type 2 diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Type 2 diabetes mellitus define fast glucose ≥ 126 mg/dl HbA1c ≥ 6.5 % blood glucose lower medication Age 18 75 year Male Female patient ( female child bear potential must use adequate contraceptive precaution ) Females childbearing potential within two year menopause must negative urine pregnancy test screen visit Informed consent ( § 40 Abs . 1 Satz 3 Punkt 3 AMG ) give write form . Any form diabetes mellitus type 2 diabetes mellitus Use insulin , glitazone , gliptine SGLT2 inhibitor within past 3 month Patients one oral blood glucose lower medication Any oral antidiabetic drug discontinue study period HbA1c ≥ 10 % Fasting plasma glucose &gt; 240 mg/dl Any history stroke , transient ischemic attack , instable angina pectoris , myocardial infarction within last 6 month prior study inclusion UACR ≥ 300 mg/g ( early morning spot urine ) eGFR &lt; 60 ml/min/1.73m² Uncontrolled arterial hypertension ( RR ≥ 180/110 mmHg ) Congestive heart failure ( CHF ) NYHA stage III IV Severe disorder gastrointestinal tract disease interfere pharmacodynamics pharmakinetics study drug Significant laboratory abnormality SGOT SGPT level 3 x upper limit normal range Drug alcohol abusus Pregnant breastfeeding patient Use loop diuretic History repetitive urogenital infection per year Body mass index &gt; 40 kg/m² Triglyceride level &gt; 1000 mg/dl HDLcholesterol level &lt; 25 mg/dl Any patient currently receive chronic ( &gt; 30 consecutive day ) treatment oral corticosteroid History epilepsia history seizures Patients treat severe auto immune disease e.g . lupus Participation another clinical study within 30 day prior visit 1 Individuals risk poor protocol medication compliance Subject give write consent , pseudonymous data transfer line duty documentation duty notification accord § 12 § 13 GCPV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Empagliflozin</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Macro- Microcirculation</keyword>
	<keyword>Vascular Improvement</keyword>
	<keyword>Endothelium function</keyword>
</DOC>